Matching to adjust for biases when comparing exposed to unexposed patients, including
BMI, age, study site, and comorbidities
Statistical models used to examine breast cancer incidence up to 10 years after bariatric surgery
Pre- and postmenopause
Estrogen receptor (ER) status
17,998 women with bariatric surgery | 53,889 without bariatric surgery
301 premenopausal breast cancer cases
399 postmenopausal breast cancer cases
Bariatric surgery was associated with a lower risk of breast cancer overall (P < 0.001)
Hazard ratio (HR) 0.63 (95% CI, 0.52–0.76)
Bariatric surgery was associated with a reduced risk of both premenopausal and postmenopausal breast cancer
Premenopausal: Hazard ratio (HR) 0.72 (95% CI, 0.54–0.94)
Postmenopausal: HR 0.55 (95% CI, 0.42–0.72)
In premenopausal women, the effect of surgery was more pronounced among ER-negative cases
HR 0.36 (95% CI, 0.16–0.79)
In postmenopausal women, the effect of surgery was more pronounce among ER-positive cases
HR 0.52 (95% CI, 0.39–0.70)
Bariatric surgery was associated with an 37% lower risk of breast cancer overall compared to severely obese women
This effect was significant in both pre and postmenopausal women
This study is consistent with previous studies demonstrating that weight loss is associated with reduced breast cancer risk
In addition, bariatric surgery is associated with gut microbiome changes (similar to patients with lower BMI) and there is literature suggesting there may be a relationship between gut microbial diversity and breast cancer risk
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan